AstraZeneca (LON:AZN) Share Price Passes Above 200-Day Moving Average – Here’s Why

AstraZeneca PLC (LON:AZN) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of £116.14 and traded as high as £140.92. AstraZeneca shares last traded at £138.36, with a volume of 1,772,910 shares traded.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on AZN shares. Jefferies Financial Group reiterated a “buy” rating and issued a £150 price objective on shares of AstraZeneca in a research report on Monday, November 10th. Shore Capital reaffirmed a “buy” rating and issued a £145 price target on shares of AstraZeneca in a research note on Thursday, November 6th. Berenberg Bank boosted their price objective on shares of AstraZeneca from £142 to £145 and gave the company a “buy” rating in a research report on Tuesday, October 21st. Finally, JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a report on Monday, November 10th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of £137.50.

AstraZeneca Stock Down 0.8%

The company has a market capitalization of £212.82 billion, a P/E ratio of 25.85, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a 50-day moving average of £127.79 and a two-hundred day moving average of £116.14. The company has a quick ratio of 0.59, a current ratio of 0.93 and a debt-to-equity ratio of 73.83.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.